Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer

Patients with extensive-stage small cell lung cancer don’t have a lot of options. When the FDA last March approved Roche’s Tecentriq to treat new patients, it was the first green light for that group in more than 20 years. But that didn’t convince England’s cost watchdogs to foot the bill.